The global enteral feeding formulas market size is expected to reach USD 9.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.9% from 2021 to 2028. The growing prevalence of chronic diseases such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes is projected to drive the demand for products that support patients with oral intake issues. In addition, the rise in preterm births is one of the significant factors boosting the demand for enteral feeding formulas to meet the nutritional requirements of newborns.

Based on product, the standard formulas segment dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a vast variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Request FREE Sample Report: https://www.grandviewresearch.com/industry-analysis/enteral-feeding-formulas-market

Enteral Feeding Formulas Market Report Highlights

• The market is anticipated to grow over the forecast period owing to the growing prevalence of chronic diseases and the rise in preterm births
• The standard formulas segment dominated the market in 2020, owing to the availability of a wide variety of standard formulas coupled with increased demand for low-cost nutrient formulations
• The intermittent feeding flow segment dominated the market in 2020, owing to better tolerance in patients shown by intermittent flow as compared to bolus feeding
• Adults accounted for the largest revenue share in the market in 2020 owing to the rising adoption of tube feeds in the adults and the availability of a large number of tube feeds or products for adults on the commercial level
• Other indications followed by cancer care accounted for the largest share in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote market growth
• The homecare segment accounted for the highest revenue share in the market owing to the rising number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition
• North America dominated the market with a revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions

Key Companies & Market Share Insights

The market is characterized by the presence of leading players with strong product portfolios, global presence, and financial performance. For instance, Abbott, headquartered in the U.S. markets and sells its products in more than 150 countries across the globe. In addition, companies are strategically collaborating with other players in the market, in the form of mergers and partnerships, for leveraging their technological capabilities and expanding their product portfolios of enteral foods. Moreover, major players are continuously investing in R&D activities for the development of new products that cater to niche therapeutic areas with higher growth potential to gain a competitive edge. In addition, market entry is challenging for new players as space is dominated by major MNCs with high brand recognition. Some of the prominent players in the enteral feeding formulas market include Abbott, Danone SA, Fresenius Kabi, Nestlé, Victus, Inc., Primus Pharmaceuticals, Inc., Meiji Holdings. Co., Ltd., Rickett Benckiser Group Plc.

Browse Full Report (Tables & Figures) @ https://www.grandviewresearch.com/industry-analysis/enteral-feeding-formulas-market